Europe gives generics merger the green flag


 

Two of the top five global generic medicines manufactures, Watson and Actavis, have been given the go-ahead to merge by the European Commission. Under the deal, Watson – which is predominantly active in the US – will acquire Actavis for €4.25 billion (£3.4 billion).

The combined company will become the third largest generics business in the world, after Israel’s Teva, and Sandoz, the generics arm of Swiss firm Novartis. According to Watson’s chief executive, Paul Bisaro, the aim of the acquisition is to strengthen the company’s position outside of the US. ‘In a single, commercially compelling transaction, we more than double Watson's international access and strengthen our commercial position in key established European markets as well as exciting emerging growth markets, including Central and Eastern Europe and Russia,’ he says.


Related Content

Megamerger brings Actavis into R&D race

25 February 2014 Business

news image

$25bn Forest Labs takeover will see generics giant take on patented products

Business roundup

28 July 2011 Business

news image

Industry news, August 2011

Most Read

Bubble wrap could send lab costs packing

23 July 2014 Research

news image

Potential bubbles up across wide range of uses as storage and test vessels, especially for poor countries

Coffee cup confusion

20 July 2014 Research

news image

Scientists call for better labelling after research highlights inconsistencies in the chemical composition of a cup of coffee

Most Commented

Bubble wrap could send lab costs packing

23 July 2014 Research

news image

Potential bubbles up across wide range of uses as storage and test vessels, especially for poor countries

Relativity behind mercury's liquidity

21 June 2013 Research

news image

First evidence that relativistic effects are indeed responsible for mercury's low melting point